- Eli Lilly (NYSE: LLY) to Acquire Ajax Therapeutics for Up to $2.3B to Advance Myelofibrosis and Polycythemia Vera Pipeline. Eli Lilly (LLY) has entered into a definitive agreement to acquire Ajax Therapeutics, gaining its lead next-generation Type II JAK2 inhibitor AJ1-11095, currently in Phase 1 for myelofibrosis. The total consideration could reach $2.3 billion, including upfront payment and clinical/regulatory milestones. The acquisition continues Lilly’s aggressive oncology buildout and targets patients who have progressed on existing JAK inhibitors. Lilly plans to rapidly advance AJ1-11095 into later-stage trials leveraging its hematology expertise. (Link)
- IKS Health Announces Agreement to Acquire TruBridge (NASD: TBRG) for ~$391–565 M. IKS Health has entered into a definitive agreement to acquire TruBridge, Inc., a leading provider of revenue cycle management (RCM) and electronic health record (EHR) solutions for rural and community hospitals. TruBridge shareholders will receive $26.25 per share in cash. The deal combines IKS Health’s agentic AI and care enablement capabilities with TruBridge’s deep expertise serving over 1,500 rural providers, creating a stronger platform for more than 2,000 healthcare organizations and 150,000 clinicians. The transaction is expected to close in Q3 2026, subject to shareholder and regulatory approvals. (Link)
- Ligand Pharmaceuticals (NASD: LGND) to Acquire XOMA Royalty for $739M. Ligand (LGND) has agreed to acquire XOMA Royalty (XOMA) for $39.00 per share in cash, representing an equity value of approximately $739 million, plus a contingent value right tied to ongoing litigation proceeds. The transaction expands Ligand’s royalty portfolio to over 200 assets and adds seven new commercial products. The deal is expected to be immediately accretive to Ligand’s earnings and further cements its position as a leading biopharma royalty aggregator. Closing is anticipated in Q3 2026. (Link)
- Thermo Fisher Scientific (NYSE: TMO) Agrees to Sell Microbiology Business to Astorg for Approximately $1.08 B. Thermo Fisher (TMO) has signed a definitive agreement to divest its microbiology business to private equity firm Astorg for ~$1.075 billion in cash plus a $50 million seller note. The business provides antimicrobial susceptibility testing and culture media products used in clinical, pharmaceutical, and food safety applications. The transaction is expected to close in the second half of 2026 and will be dilutive to Thermo Fisher’s adjusted EPS by $0.15 in the first full year post-close. (Link)
- Invidia Capital Makes Growth Capital Investment in WIN, a Leading Fertility and Family-Building Benefits Platform. Invidia Capital Management, a newly formed healthcare-focused private equity firm, has signed its first investment — a growth capital deal in WIN Holding Corporation, a leading fertility and family-building benefits provider. WIN serves over 900,000 families with a clinical-first model covering fertility treatment, surrogacy, adoption, maternity, menopause, and return-to-work programs. The investment is subject to regulatory approvals; WIN’s founder and CEO Dr. Roger Shedlin will continue leading the company. (Link)
- CVC Capital Partners and GTCR are reportedly exploring a take-private acquisition of Teleflex Incorporated (NYSE: TFX) as private equity interest in large-scale medical device manufacturers intensifies Global private equity firms CVC Capital Partners and GTCR are weighing a potential take-private deal for Teleflex Incorporated (TFX), a prominent manufacturer of medical devices for vascular and interventional access. This multi-billion dollar interest reflects a trend where private equity seeks to acquire large, cash-generative public medical technology companies. Teleflex (TFX) is viewed as an attractive target due to its diversified product portfolio and strong global market position. Investors are watching closely as a successful deal would require a significant premium over current trading prices. If the acquisition proceeds, CVC and GTCR would likely focus on operational restructuring and product line expansion to maximize the company’s long-term value in a private setting. (Link)
- Clearlake Capital-Backed ModMed (Modernizing Medicine) Acquires Bonsai Health, an Agentic AI Patient Engagement Platform, with Support from Financial Sponsors Project A Ventures, CPP Investments, and Golub Capital ModMed, a leading provider of cloud-based EHR software for specialty medical practices, has acquired Bonsai Health to bolster its AI-powered practice management capabilities. Backed by Clearlake Capital Group (with over $185 billion in AUM), along with co-sponsors Project A Ventures, CPP Investments, and Golub Capital, ModMed plans to deploy Bonsai’s agentic AI technology across its network of nearly 50,000 specialty providers in dermatology, ophthalmology, orthopedics, and gastroenterology. Bonsai’s platform automates patient reactivation and self-scheduling via multi-channel SMS and email without manual staff intervention. The acquisition brings former PatientPop co-founders Travis Schneider and Luke Kervin into the ModMed fold. Financial terms were not disclosed. (Link)
- Covera Health and Medmo have merged to create a unified data-driven platform focused on improving diagnostic imaging quality and patient access across the healthcare systemThe merger of Covera Health and Medmo creates a powerful new player in the diagnostic services market, combining Covera’s quality-analytics with Medmo’s navigation platform. This strategic combination is designed to ensure that patients are directed to high-quality imaging centers, reducing the incidence of misdiagnosis. Investors are backing this merger as it addresses the $100 billion problem of radiology inefficiency. The combined entity will leverage its data assets to partner with health plans and large employers, offering a value-based imaging solution. This deal highlights the investment trend of merging “access” platforms with “quality” analytics to create a more comprehensive health-tech solution that reduces overall payer costs. (Link)
- Oura has acquired Galen AI to integrate advanced metabolic health tracking and artificial intelligence capabilities into its market-leading wearable health platform. Oura has completed the acquisition of Galen AI, a strategic move that brings advanced artificial intelligence and metabolic health expertise into the Oura ecosystem. This investment is part of Oura’s transition from a wellness-focused ring to a clinical-grade health monitoring tool. By integrating Galen AI’s technology, Oura plans to offer users deeper insights into their metabolic data, potentially tracking glucose trends and other vital markers. (Link)
- Advanced RevCycle, via its financial sponsors Kolos Partners and Perkin Industries, completed a leveraged buyout of Select RCM Services and Select Health to expand its AI-driven revenue cycle management footprint. Advanced RevCycle has successfully executed a leveraged buyout of Select RCM Services and its specialized division, Select Health AI. This acquisition is strategically backed by financial sponsors Kolos Partners and Perkin Industries, who are providing the necessary capital to scale AI-driven billing and claims processing solutions. By integrating Select Health AI’s proprietary algorithms, Advanced RevCycle aims to reduce administrative friction for healthcare providers, a sector that investors see as ripe for automation-led growth. The deal reflects the ongoing investment thesis that specialized RCM platforms can achieve higher margins through the deployment of autonomous financial workflows. (Link)
- Aqua Dermatology, backed by financial sponsors Gryphon Investors, GTCR, and Athyrium Capital Management, has acquired Steele Dermatology Private equity heavyweights Gryphon Investors, GTCR, and Athyrium Capital Management continue to support the expansion of Aqua Dermatology through the strategic acquisition of Steele Dermatology. This leveraged buyout allows Aqua Dermatology to absorb a premium clinical practice into its platform, leveraging the sponsors’ deep expertise in healthcare service roll-ups. The investment is focused on scaling Aqua’s geographic presence and centralizing administrative functions to improve clinical throughput. Investors view the dermatology sector as a resilient asset class, where consolidating independent practices under a well-funded corporate umbrella creates significant value through purchasing power and standardized care protocols. (Link)
- Parkview Dental Partners, via its financial sponsors Barings, Barings Capital Investment BDC, and Cathay Capital, has acquired VIP Dental through a leveraged buyout on April 23, 2026, to scale its comprehensive and emergency dental care network. Parkview Dental Partners has expanded its reach in Florida by acquiring VIP Dental, a deal facilitated by a leveraged buyout with backing from Barings and Cathay Capital. The financial sponsors are providing the capital to integrate VIP Dental’s emergency and general dentistry services into Parkview’s broader Dental Service Organization (DSO) model. Investors like Barings Capital Investment BDC are particularly interested in the dental sector due to its recurring revenue and the opportunity for operational consolidation. By providing VIP Dental with professional management resources and advanced imaging technologies, the sponsors aim to drive organic growth and capture a larger share of the regional dental market. (Link)
- AdvaHealth has acquired the FlexView platform from Radical Imaging to launch AdvaView, a new cloud-native enterprise imaging and PACS solution for medical providers. AdvaHealth’s acquisition of FlexView from Radical Imaging represents a major strategic investment in the medical imaging software market. By acquiring this technology, AdvaHealth is launching “AdvaView,” a solution designed to provide healthcare systems with more flexible, cloud-based Picture Archiving and Communication Systems (PACS). The investment focuses on the growing need for interoperability and remote access to diagnostic data. Investors in the med-tech space are increasingly backing “asset-light” software solutions that can replace legacy on-premise hardware. AdvaHealth aims to use this acquisition to position itself as a leader in digital diagnostics, providing a scalable platform that improves radiologist efficiency and patient data security. (Link)
- Primary Health Solutions has announced a definitive agreement to acquire South Community Behavioral Health to expand its integrated mental and behavioral health services. Primary Health Solutions is investing in the expansion of its behavioral health footprint through the acquisition of South Community Behavioral Health. This deal reflects the growing investor interest in “whole-person care” models that integrate primary medical services with mental health support. By acquiring this regional provider, Primary Health Solutions aims to meet the surging demand for behavioral therapy while streamlining clinical workflows. The acquisition is expected to create significant synergies by allowing for a more coordinated approach to patient management. This transaction underscores the high value of community-based behavioral health assets as essential pillars for diversified organizations looking to thrive under value-based care contracts. (Link)
Venture Deals and Other
- Tava Health has raised $40 M in a Series C funding round led by Centana Growth Partners, with participation from Catalyst Investors, Blue Heron Ventures, Peterson Ventures, and Springtide Ventures. Tava Health has secured $40 million in Series C financing to expand its mental health platform, which connects individuals with specialized clinical care. The round was led by Centana Growth Partners and included a strong syndicate of investors such as Catalyst Investors and Peterson Ventures. This investment will enable Tava Health to grow its provider network and enhance its tech-enabled platform, which focuses on delivering high-quality mental health outcomes for employees and health plan members. Investors are drawn to Tava’s focus on provider satisfaction and clinical results, which have driven its rapid adoption by large corporations. This funding round underscores the continued strength of the mental health tech sector as a top priority for venture capital. (Link)
- Seaport Therapeutics Files for $212 M IPO (NASD: SPTX). Seaport Therapeutics, a clinical-stage biotech focused on novel antidepressants and anxiety treatments, is seeking to raise up to $212.4 million by offering 11.8 million shares priced between $16 and $18 each. The Boston-based company, a PureTech Health-founded entity, targets a ~$912 million valuation at the top of the range. Proceeds will advance its neuropsychiatric pipeline. This marks one of the more notable biotech IPOs of 2026. (Link)
- Nervonik Raises $52.5 M in Series B to Advance Peripheral Nerve Stimulation Therapy. Nervonik, a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system for chronic pain, announced a $52.5 million Series B round. The funding will support clinical studies, regulatory clearance, and commercialization of its next-generation miniaturized technology. This round builds on the company’s prior $13 million Series A and reflects continued investor enthusiasm for innovative neuromodulation solutions. (Link)
- TMRW Life Sciences has raised $38.359 M in new funding to expand its automated and digitized platform for the management of frozen specimens in the fertility industry. TMRW Life Sciences has secured over $38 million in a recent funding round, as detailed in SEC filings, to accelerate the global adoption of its automated cryo-management platform. TMRW’s technology replaces manual processes in IVF clinics with a digitized tracking and storage system for eggs and embryos, significantly reducing the risk of specimen loss or error. This investment reflects the strong venture interest in the fertility sector, where technology is increasingly used to bring scale and safety to complex lab environments. The capital will support TMRW’s commercial expansion and product development, as more clinics seek to modernize their operations to meet the rising global demand for IVF services, making TMRW an essential infrastructure partner. (Link)
- Zocalo Health has closed a $15 million Series A round led by EO Ventures, with participation from Talipot, Vamos Ventures, Animo Ventures, Acumen America, Sorenson Ventures, BarronKent, and Kapor Center. Zocalo Health has raised $15 million in Series A funding to scale its community-based primary care model for Latino populations. Led by EO Ventures, the round included a diverse group of investors like Vamos Ventures and Acumen America, who are focused on health equity and underserved markets. Zocalo Health uses a “trust-based” model that combines community health workers with a specialized technology platform to drive better health outcomes. This investment will be used to expand Zocalo’s footprint and clinical teams, addressing the critical need for culturally competent care. Investors see Zocalo’s approach as a blueprint for high-impact, value-based primary care that can successfully engage high-need populations who have been historically overlooked by traditional healthcare systems. (Link)
- Amperos Health has raised $16 million in a Series A round led by Bessemer Venture Partners, with participation from Uncork Capital and Neo, to scale its AI-native revenue recovery platform. Amperos Health, a developer of AI-native software for medical denial management, has secured $16 million in Series A funding. The round was led by Bessemer Venture Partners, a firm known for its investments in high-growth SaaS and AI companies. Uncork Capital and Neo also joined the round, signaling strong institutional support for Amperos’ “agentic” AI approach to revenue cycle management. The capital will be used to expand the company’s engineering team and accelerate the deployment of its platform, which automates the complex insurance appeal process. Investors are betting that Amperos can significantly reduce administrative overhead for hospitals, capturing a massive market opportunity in healthcare’s inefficient financial back-office. (Link)
- Coral has secured $12.5 million in funding led by Z47 and Lightspeed to accelerate the growth of its innovative healthcare fintech and payment processing solutions. Fintech startup Coral has raised $12.5 million in a new funding round led by prominent venture firms Z47 and Lightspeed. The investment is aimed at transforming the healthcare payment landscape by providing a more transparent and user-friendly billing platform for both providers and patients. Coral’s technology integrates with clinical workflows to simplify collections and insurance processing, a sector where investors see immense potential for disruption. Coral plans to scale its sales and marketing efforts and further develop its product features. Lightspeed’s involvement underscores the high confidence in Coral’s ability to solve the long-standing friction in medical billing, creating a more efficient financial ecosystem for the healthcare industry. (Link)
- Cerracap Ventures has invested in Nephronomics to accelerate the development of its AI-driven discovery platform for chronic kidney disease. Nephronomics has received a strategic investment from Cerracap Ventures to advance its groundbreaking AI platform, which focuses on identifying early biomarkers for chronic kidney disease (CKD). The platform uses proprietary algorithms to help pharmaceutical companies and clinicians discover new therapeutic targets, a field that investors see as having massive commercial potential. This capital will support Nephronomics’ efforts to validate its findings and expand its clinical partnerships. Cerracap Ventures’ investment reflects the growing interest in precision medicine and AI-led diagnostics for complex diseases. By funding the development of this discovery engine, investors aim to transform the standard of care for millions of CKD patients worldwide, moving toward earlier and more effective interventions. (Link)
- Capital QR Ventures has invested in Mia Health as the company launches a new funding round to support its digital health and patient wellness platform expansion. Mia Health has received a strategic investment from Capital QR Ventures to fuel its growth in the digital wellness and personalized health insights market. This funding is part of a broader round aimed at enhancing Mia Health’s data analytics capabilities and expanding its user base. Investors like Capital QR Ventures are backing Mia Health due to its ability to leverage biometric data to provide actionable health recommendations to consumers. The capital will be used to develop new features and strengthen the platform’s integration with healthcare providers, positioning Mia Health as a key player in the preventative care space. This transaction reflects the ongoing venture trend of investing in tech-driven wellness solutions that prioritize long-term health outcomes. (Link)
- Gravity Rail has raised $2.75 million in seed funding from Redesign Health to launch its AI-powered patient engagement platform for automated healthcare workflows. Gravity Rail has officially launched with $2.75 million in seed capital provided by Redesign Health. The startup’s platform offers a model-agnostic operating system that allows healthcare organizations to build and manage their own AI-powered patient communications. This investment is part of Redesign Health’s strategy to back innovative infrastructure that empowers medical providers to take control of their digital interactions. Gravity Rail’s technology enables clinical teams to automate tasks across multiple channels without writing code, ensuring consistent patient engagement and compliance. Investors view Gravity Rail as a vital tool for health systems looking to scale their operations while maintaining high standards of clinical communication and patient safety. (Link)
- Magicare has emerged from stealth with $3.6 million in pre-seed funding to develop its agentic operating system for the healthcare and pharmaceutical sectors. Magicare has secured $3.6 million in pre-seed capital to build a specialized AI operating system designed for the complex needs of the healthcare and pharmaceutical industries. This early-stage investment will support the development of autonomous AI agents that can manage operational workflows, from clinical trials to patient administration. Magicare’s focus on building a secure, compliant OS is particularly attractive to investors who see a gap in the market for AI that can function within highly regulated environments. This deal highlights the growing venture interest in “agentic” AI that moves beyond simple chatbots into true task-oriented automation. (Link)
- Dentscape and Preteeth AI Pro expect to receive $0.2 million in funding from ASO to advance their collaborative development of AI-driven dental diagnostic technologies. Dentscape and Preteeth AI Pro are set to receive a strategic $0.2 million investment from ASO to further their joint efforts in AI dental imaging and diagnostics. This funding is focused on enhancing the accuracy of automated diagnostic tools, allowing dentists to better identify and communicate oral health issues to patients. While an early-stage investment, it highlights the growing role of AI in dental specialty services. Investors are increasingly backing niche AI applications that can improve clinical precision and office productivity. Dentscape and Preteeth AI Pro aim to use this capital to refine their diagnostic algorithms, ultimately positioning their technology as a standard tool for modern dental practices seeking to improve patient outcomes and trust. (Link)